Cumberland Pharmaceuticals Inc. enters into a definitive agreement to acquire the FDA-approved oncology-supportive care medicine SANCUSO® from Kyowa Kirin Inc. the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. Under the terms of the agreement, Cumberland will acquire U.S. rights to SANCUSO and will assume full commercial responsibility for the product including its marketing, promotion, distribution, manufacturing and medical support activities. Net sales of the brand in the U.S. were over $14 million in 2020. The financial terms of the acquisition include a $13.5 million payment to Kyowa Kirin upon closing, up to $3.5 million in milestones and tiered royalties of up to 10% on U.S. net product sales.
Kyowa Kirin will retain international rights, continuing to deliver the product to address oncology patients' needs throughout the rest of the world.